 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Diacrin, Inc.
 |
Diacrin, Inc. |
 |
 |
 |
PROFILE |
 |
Diacrin goes hog wild treating diseases. The development-stage company concentrates on cell therapy, using pig cells to develop therapies for people; it is also developing technologies to prevent human bodies from rejecting transplanted pig cells. In 1995 the firm conducted the first clinical trials of such xenotransplants. Through a joint venture with Genzyme, Diacrin is developing treatments for Parkinson's and Huntington's diseases. The company is also working on treatments for epilepsy, stroke, spinal cord injuries, liver disease, and cardiac disease. Healthcare-focused venture capital firm HealthCare Ventures owns 25% of Diacrin.
COMPETITION |
 |
Guilford Pharmaceuticals Inc. (GLFD)
NeoTherapeutics, Inc. (NEOT)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.20
1-Yr. Sales Growth: 73.3%
Employees: 38
Revenue per employee: $136,842.11
KEY PEOPLE |
 |
Thomas H. Fraser
CEO
CONTACT INFO |
 |
Charlestown Navy Yard, Bldg. 96, 13th St.
Charlestown, MA 02129
US
Phone: 617-242-9100
Fax: 617-242-0070
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |